307 related articles for article (PubMed ID: 30270813)
1. Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment.
Ma J; Huo X; Jarpe MB; Kavelaars A; Heijnen CJ
Acta Neuropathol Commun; 2018 Oct; 6(1):103. PubMed ID: 30270813
[TBL] [Abstract][Full Text] [Related]
2. Protective Effects of ACY-1215 Against Chemotherapy-Related Cognitive Impairment and Brain Damage in Mice.
Wang D; Wang B; Liu Y; Dong X; Su Y; Li S
Neurochem Res; 2019 Nov; 44(11):2460-2469. PubMed ID: 31571096
[TBL] [Abstract][Full Text] [Related]
3. HDAC6 inhibition reverses long-term doxorubicin-induced cognitive dysfunction by restoring microglia homeostasis and synaptic integrity.
McAlpin BR; Mahalingam R; Singh AK; Dharmaraj S; Chrisikos TT; Boukelmoune N; Kavelaars A; Heijnen CJ
Theranostics; 2022; 12(2):603-619. PubMed ID: 34976203
[TBL] [Abstract][Full Text] [Related]
4. HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy.
Krukowski K; Ma J; Golonzhka O; Laumet GO; Gutti T; van Duzer JH; Mazitschek R; Jarpe MB; Heijnen CJ; Kavelaars A
Pain; 2017 Jun; 158(6):1126-1137. PubMed ID: 28267067
[TBL] [Abstract][Full Text] [Related]
5. Pifithrin-μ Prevents Cisplatin-Induced Chemobrain by Preserving Neuronal Mitochondrial Function.
Chiu GS; Maj MA; Rizvi S; Dantzer R; Vichaya EG; Laumet G; Kavelaars A; Heijnen CJ
Cancer Res; 2017 Feb; 77(3):742-752. PubMed ID: 27879267
[TBL] [Abstract][Full Text] [Related]
6. Nasal administration of mitochondria reverses chemotherapy-induced cognitive deficits.
Alexander JF; Seua AV; Arroyo LD; Ray PR; Wangzhou A; Heiβ-Lückemann L; Schedlowski M; Price TJ; Kavelaars A; Heijnen CJ
Theranostics; 2021; 11(7):3109-3130. PubMed ID: 33537077
[TBL] [Abstract][Full Text] [Related]
7. Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice.
Zhang L; Liu C; Wu J; Tao JJ; Sui XL; Yao ZG; Xu YF; Huang L; Zhu H; Sheng SL; Qin C
J Alzheimers Dis; 2014; 41(4):1193-205. PubMed ID: 24844691
[TBL] [Abstract][Full Text] [Related]
8. HDAC6 Inhibition Reverses Cisplatin-Induced Mechanical Hypersensitivity via Tonic Delta Opioid Receptor Signaling.
Zhang J; Junigan JM; Trinh R; Kavelaars A; Heijnen CJ; Grace PM
J Neurosci; 2022 Oct; 42(42):7862-7874. PubMed ID: 36096670
[TBL] [Abstract][Full Text] [Related]
9. Developmental neurotoxicity in the context of multiple sevoflurane exposures: Potential role of histone deacetylase 6.
Li G; Du J; Wang L; Shi X
Neurotoxicol Teratol; 2019; 74():106813. PubMed ID: 31251981
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth.
Van Helleputte L; Kater M; Cook DP; Eykens C; Rossaert E; Haeck W; Jaspers T; Geens N; Vanden Berghe P; Gysemans C; Mathieu C; Robberecht W; Van Damme P; Cavaletti G; Jarpe M; Van Den Bosch L
Neurobiol Dis; 2018 Mar; 111():59-69. PubMed ID: 29197621
[TBL] [Abstract][Full Text] [Related]
11. HDAC6 inhibition results in tau acetylation and modulates tau phosphorylation and degradation in oligodendrocytes.
Noack M; Leyk J; Richter-Landsberg C
Glia; 2014 Apr; 62(4):535-47. PubMed ID: 24464872
[TBL] [Abstract][Full Text] [Related]
12. Blockade of histone deacetylase 6 protects against cisplatin-induced acute kidney injury.
Tang J; Shi Y; Liu N; Xu L; Zang X; Li P; Zhang J; Zheng X; Qiu A; Zhuang S
Clin Sci (Lond); 2018 Feb; 132(3):339-359. PubMed ID: 29358506
[TBL] [Abstract][Full Text] [Related]
13. An HDAC6-dependent surveillance mechanism suppresses tau-mediated neurodegeneration and cognitive decline.
Trzeciakiewicz H; Ajit D; Tseng JH; Chen Y; Ajit A; Tabassum Z; Lobrovich R; Peterson C; Riddick NV; Itano MS; Tripathy A; Moy SS; Lee VMY; Trojanowski JQ; Irwin DJ; Cohen TJ
Nat Commun; 2020 Nov; 11(1):5522. PubMed ID: 33139698
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of HDAC6 modifies tau inclusion body formation and impairs autophagic clearance.
Leyk J; Goldbaum O; Noack M; Richter-Landsberg C
J Mol Neurosci; 2015 Apr; 55(4):1031-46. PubMed ID: 25434725
[TBL] [Abstract][Full Text] [Related]
15. HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease.
Benoy V; Van Helleputte L; Prior R; d'Ydewalle C; Haeck W; Geens N; Scheveneels W; Schevenels B; Cader MZ; Talbot K; Kozikowski AP; Vanden Berghe P; Van Damme P; Robberecht W; Van Den Bosch L
Brain; 2018 Mar; 141(3):673-687. PubMed ID: 29415205
[TBL] [Abstract][Full Text] [Related]
16. A novel HDAC6 inhibitor interferes microtubule dynamics and spindle assembly checkpoint and sensitizes cisplatin-induced apoptosis in castration-resistant prostate cancer.
Ye PC; Leu WJ; Yeh TY; Hsu YT; Lin YC; Wei ZY; Chen YC; Chiang YC; Hsu JL; Chan SH; Hsu LC; Chern JW; Yu CW; Guh JH
Prostate; 2024 May; 84(6):605-619. PubMed ID: 38375594
[TBL] [Abstract][Full Text] [Related]
17. A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer's disease and tauopathy in mice.
Onishi T; Maeda R; Terada M; Sato S; Fujii T; Ito M; Hashikami K; Kawamoto T; Tanaka M
Sci Rep; 2021 Jul; 11(1):15423. PubMed ID: 34326423
[TBL] [Abstract][Full Text] [Related]
18. Cell-specific role of histone deacetylase 6 in chemotherapy-induced mechanical allodynia and loss of intraepidermal nerve fibers.
Ma J; Trinh RT; Mahant ID; Peng B; Matthias P; Heijnen CJ; Kavelaars A
Pain; 2019 Dec; 160(12):2877-2890. PubMed ID: 31356453
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy accelerates age-related development of tauopathy and results in loss of synaptic integrity and cognitive impairment.
Chiang ACA; Huo X; Kavelaars A; Heijnen CJ
Brain Behav Immun; 2019 Jul; 79():319-325. PubMed ID: 30953771
[TBL] [Abstract][Full Text] [Related]
20. Tau--an inhibitor of deacetylase HDAC6 function.
Perez M; Santa-Maria I; Gomez de Barreda E; Zhu X; Cuadros R; Cabrero JR; Sanchez-Madrid F; Dawson HN; Vitek MP; Perry G; Smith MA; Avila J
J Neurochem; 2009 Jun; 109(6):1756-66. PubMed ID: 19457097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
